Medlevate — Intelligence Platform

ME

Medlevate

Commercialization Intelligence

Loading…

Alerts

No alerts yet

Pricing

Choose the plan that fits your research needs

Simple, transparent pricing

Replace the $50,000 consultant call. Cancel anytime.

Explorer

$49/month

For individual researchers and first-time innovators

✓ 5 Market Analysis reports/month
✓ Full Market Discovery access (1,400+ diseases ranked)
✓ Idea Builder — profile-to-market matching
✓ TAM/SAM derivation with every formula step shown
✓ FDA regulatory pathway + expedited designations
✓ 40+ data sources cited per report
✓ PDF export
✗ AI fact-checking validation
✗ Development timeline with iCal export
✗ Saved reports history

MOST POPULAR

Innovator

$149/month

For active researchers, health innovators, and early-stage founders running multiple analyses

✓ 20 Market Analysis reports/month
✓ Everything in Explorer
✓ AI fact-checking — LangGraph independent validation
✓ Development timeline with iCal export
✓ Saved reports history — access past analyses anytime
✓ 49-source database: NCI SEER, CMS, Orphanet, NICE, cBioPortal + more
✓ Competitive intelligence sweep — named products, pipeline gaps
✓ Strategic playbook — precedent-grounded FDA timelines

FOR BIOTECH TEAMS

Professional

Contact for pricing

For tech transfer offices, investment teams, and consulting firms evaluating high volumes of innovations

✓ Unlimited intelligence reports
✓ Everything in Innovator
✓ Institutional memory — analyses improve over time
✓ PubMed landmark publications in every report
✓ Weekly competitive intelligence digest (email)
✓ Priority support

Frequently asked questions

How is this different from asking ChatGPT?

Medlevate uses 32 domain-specific expert profiles, pulls live data from FDA.gov, ClinicalTrials.gov, CDC, and PubMed at report time, and validates every claim with an independent AI critic. ChatGPT gives generic answers with no citations and can't access current regulatory data.

Can I cancel anytime?

Yes. Cancel from your profile page and you keep access until the end of your billing period.

What counts as an "analysis"?

Each market analysis run counts as one use. Saved reports don't count - only new runs.

How do I get access?

Click "Request Access" on any plan and we'll set up your account manually. Online billing is coming soon — early access members get priority onboarding.

Commercialization Intelligence

Bottom-up market sizing, FDA pathway analysis, competitive landscape, and commercial strategy — for any health innovation, grounded in primary sources.

Product SubmissionSelect type below

Select product type

Life Sciences Clinical

Life Sciences Research

Describe your product

Target pathogen (antibiotics)

Quick examples

Analysis Output-

🔔 Get weekly alerts when new signals match this topic

✓ Analysis complete

⚕

No analysis yet

Select a product type and describe your innovation to generate a full intelligence report with market sizing, regulatory pathway, and source citations.

Opportunity Discovery

What these numbers mean

SAM — Serviceable Addressable Market

What a company can realistically earn at Year 5 after launch — after accounting for insurance coverage restrictions, real-world patient adherence, market adoption speed, and approval probability. This is the most important number — used to rank diseases.

TAM — Total Addressable Market

The theoretical maximum — if every eligible patient paid full list price simultaneously. This number is always larger than what you can actually earn, because it ignores insurance restrictions, patients who never fill prescriptions, and competition. Think of it as the ceiling, not the target.

PTRS — Approval Probability

The historical odds of a drug or device reaching FDA approval from its current stage, based on tracking 14,656 programs from 2011–2020. Example: only 1 in 20 cancer drugs that enter human trials ever get approved. Hematology drugs succeed ~1 in 4 times. Medical devices clear ~54% of the time — their bar is lower.

Opportunity / Probability / Value bars

Opportunity — how badly medicine needs a solution here (no treatments = high; crowded market = low). Probability — how likely a drug actually makes it through trials and gets approved. Value — how large the realistic revenue is relative to blockbuster drugs. All three are 0–100.

Tier labels (Exceptional / High / Moderate / Low)

A convenience rating combining all three bars into one label. Exceptional means all three factors are strong simultaneously — rare. High means strong but with one meaningful limitation. Moderate is worth exploring but has clear challenges. Low has significant barriers in at least two dimensions.

Commercial path badge

● Validated market — at least 3 drugs already approved here; the commercial path is proven. ● Viable path — emerging clinical interest with some approvals. ● Emerging — 0 approved therapies but active trial interest. ● Speculative — 0 approved, very few trials; scientifically interesting but no one has successfully built a commercial business here yet.

Scoring methodology

Show ▾

8-criterion MCDA — grounded in EVIDEM v3.0 (Goetghebeur et al., PMC3192743) + Advanced Market Sizing Framework (DisMod · BLP · UCRCD · BIA)

Weights derived from: EVIDEM v3.0 domain consensus · BIO/Informa 2011–2020 success rates · Wong, Siah & Lo (Biostatistics 2019) · Mauskopf BIA (ISPOR) · ICER reference case

Disease Severity & Burden 18%

DALYs (WHO GHO) + mortality + prevalence. EVIDEM Domain 1a. Gillum 2011: DALYs best predictor of research investment.

Unmet Medical Need 16%

Inverse of approved therapies + treatment gap. EVIDEM Domain 1b. Scores 100 when no alternatives exist; 20 when ≥7 approved agents.

Clinical Success (PTRS) 15%

Phase-specific LOA × TA multiplier × biomarker boost. BIO 2011–2020: P1 overall 7.9%, hematology 23.9%, oncology 5.3%. Wong 2019: 13.8%.

Comparative Efficacy 12%

Mechanism novelty + biomarker selection + first-in-class premium. EVIDEM Domain 2. BIO: biomarker-selected programs have 3× LOA.

Economic Value & Revenue 14%

5-stage market sizing: DisMod cascade × Weibull DoT × BLP demand × Bass/UCRCD diffusion × BIA gate. EVIDEM Domain 5. ICER $150K/QALY anchor.

Competitive Dynamics 12%

Pipeline density (CT.gov live) + BLP order-of-entry share + UCRCD cross-WOM. Guseo-Guidolin 2015: b<0 cannibalization, b>0 class effect.

Regulatory & IP Position 8%

FDA designations (Orphan, Breakthrough, QIDP, RMAT) + exclusivity years. EVIDEM Domain 3. Orphan adds 7yr exclusivity; QIDP adds +5yr.

Payer Access & BIA 5%

Budget impact (Mauskopf ISPOR BIA §6): if per-patient cost >$300K or total US spend >$500M, revenue is dampened by logarithmic access restriction.

Score = (Opportunity^0.35 × Probability^0.28 × Value^0.25 × Innovation^0.12) — geometric model prevents any single near-zero factor from masking real opportunity. Confidence interval ±18–23% (Weibull DoT uncertainty). Sources: EVIDEM v3.0 (PMC3192743) · BIO/Informa 2021 · Wong et al. Biostatistics 2019 · Goetghebeur 2012 MDMA · Mauskopf ISPOR 2012.

🔍 Search diseases — type here to find any condition

Ready to discover

Click Refresh to rank biomedical markets by opportunity

Idea Builder

Tell us about your capability and we'll match you to the highest-opportunity markets, then generate a refined idea statement you can take into Market Analysis.

1

Your Profile

2

Matched Ideas

1 · What is your innovation platform?

The technology or drug type you're developing

Other:

2 · What biological mechanism or pathway does it target?

This is the most important question — it determines which diseases your innovation is most likely to work in

Other:

3 · What patient population does your work address?

Determines whether rare/orphan or large-market diseases match better

Other:

4 · Where is your work right now?

Affects which market tractability level is most appropriate for you

Other:

5 · What makes your approach unique?

Used to write your idea statement — not for disease matching

Other: